ClinicalTrials.gg
CompletedNCT04940364Updated Jul 6, 2022

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

A Phase 1 interventional study of Pozelimab and Cemdisiran in Healthy, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of the study is to assess the concentration-time profiles of total pozelimab, total C5, cemdisiran, and cemdisiran metabolite(s) in Japanese adult participants following single doses of intravenous (IV) and subcutaneous (SC) pozelimab and SC cemdisiran when administered on the same day or sequentially 28 days apart.

The secondary objectives of the study are:

  • To evaluate the safety and tolerability of pozelimab alone and in combination with cemdisiran in healthy Japanese adult participants
  • To assess the pharmacodynamic (PD) profile of pozelimab alone and in combination with cemdisiran in healthy Japanese adult participants
  • To assess the immunogenicity of pozelimab and cemdisiran in healthy Japanese adult participants
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Japanese participant must be:

    1. Be Japanese, born in Japan, and have both biologic parents and 4 biologic grandparents who are ethnically Japanese and born in Japan
    2. Have maintained a Japanese lifestyle, with no significant change since leaving Japan, including having access to Japanese food and adhering to a Japanese diet
    3. Living \< 10 years outside of Japan
  2. Has a (BMI) between 18 and 30 kg/m2 (inclusive) at screening visit
  3. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and ECGs performed at screening and/or prior to administration of initial dose of study drug
  4. Is in good health based on laboratory safety testing obtained at the screening visit Note: Participant with suspected or confirmed Gilbert's disease can be enrolled in the study
  5. Willing to undergo vaccination against N. meningitidis unless participant has documentation of completed series of vaccinations within the past 2 years of the screening visit
  6. Must have two consecutive negative COVID-19 tests at least 48 hours apart and within 7 days prior to study drug administration Note: The test may be the point of care quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) test or approved COVID-19 antigen test at the discretion of the investigator.

Key Exclusion Criteria:

  1. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator as defined in the protocol
  2. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
  3. Hospitalization (>24 hour) for any reason within 30 days of the screening visit
  4. Has a confirmed positive drug test result at the screening visit and/or prior to enrollment; or a history of alcohol and/or drug abuse within a year prior to the screening visit
  5. Is positive for (HIV), surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at the screening visit
  6. Is positive for antibody and positive for qualitative (i.e., detected) hepatitis C virus (HCV) RNA test at the screening visit
  7. Within the previous 2 months of the screening visit has a history of bacterial, protozoal, viral or parasite infection (including COVID-19) and/or persistent chronic or active recurring infection which require treatment with antibiotics, antivirals, or antifungals
  8. Known or suspected COVID-19 disease at screening and/or prior to 1st dose administration

NOTE: Other protocol-defined Inclusion and Exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Pozelimab: Single-dose SC on day 1

    Drug: Pozelimab

  • Experimental
    Cohort 2

    Pozelimab: Single-dose IV on day 1

    Drug: Pozelimab

  • Experimental
    Cohort 3

    Pozelimab: Single-dose SC on day 29 Cemdisiran: Single-dose SC on day 1

    Drug: Pozelimab · Drug: Cemdisiran

  • Experimental
    Cohort 4

    Pozelimab: Single-dose SC on day 1 Cemdisiran: Single-dose SC on day 1

    Drug: Pozelimab · Drug: Cemdisiran

  • Experimental
    Cohort 5

    Optional Pozelimab: Single-dose SC on day 1 or day 29 Cemdisiran: Single-dose SC on day 1

    Drug: Pozelimab · Drug: Cemdisiran

  • Experimental
    Cohort 6

    Pozelimab: Single-dose IV on day 1

    Drug: Pozelimab

Interventions

  • Administered intravenous (IV) or subcutaneous (SC) per protocol

    Also known as: REGN3918

  • Administered SC per protocol

    Also known as: ALN-CC5

06

What researchers measure

Primary outcomes

  1. Concentrations of pozelimab in serum over time

    Time frame: Up to 20 weeks

  2. Concentrations of cemdisiran in plasma over time.

    Time frame: Up to 20 weeks

Secondary outcomes

  1. The incidence and severity of treatment-emergent adverse events (TEAE) in subjects administered pozelimab with/without cemdisiran

    Time frame: Up to 20 weeks

  2. Concentrations of total C5 in plasma over time

    Time frame: Up to 20 weeks

  3. Change from baseline in CH50 over time

    Time frame: Up to 20 weeks

  4. Incidence of treatment-emergent anti-drug antibodies (ADA) to pozelimab

    Time frame: Up to 20 weeks

  5. Incidence of treatment-emergent ADA to cemdisiran

    Time frame: Up to 20 weeks

07

Study locations

1 site
  • Regeneron Research Site
    London, SE1 1YR, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jun 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2021
First posted
Jun 25, 2021
StartActual
Aug 4, 2021
Primary completionActual
Jun 22, 2022
CompletionActual
Jun 22, 2022
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04940364
Responsible party
Sponsor
First posted
Jun 25, 2021
Start date
Aug 4, 2021
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022
Last update
Jul 6, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion